|
|
![]() Peer-reviewed by Max. |
Brought to you by the makers of Anipryl, Clomicalm, Reconcile, and Slentrol.All information in this report was copied directly from public web sites owned by the drug companies listed above. The Bonkers Institute for Nearly Genuine Research is not responsible for any inaccuracies, misleading claims, or blatant lies contained herein. |
![]() |
clomicalm.novartis.us | |
| ||
Indications and Usage:Inappropriate barking or destructive behavior, as well as inappropriate elimination (urination or defecation) may be alleviated by the use of Clomicalm Tablets in conjunction with behavior modification.
Separation anxiety is a complex behavior disorder displayed when the owner (or other attachment figure) leaves the dog.   The signs of separation anxiety evaluated in controlled trials were vocalization, destructive behavior, excessive salivation, and inappropriate elimination.   In the absence of the owner or attachment figure, dogs with separation anxiety may exhibit one or more of these clinical signs.
| ||
Clinical PharmacologyClomicalm® (clomipramine hydrochloride) Tablets belong to the dibenzazepine class of tricyclic antidepressants. Clomipramine hydrochloride reduces the clinical signs of separation anxiety by affecting serotonergic and noradrenergic neuronal transmission in the central nervous system.   While clomipramine hydrochloride can cause lethargy in dogs (see Adverse Reactions) its mode of action is not as a sedative.   Clomipramine hydrochloride's capacity to inhibit re-uptake of serotonin in the central nervous system is believed to be the primary mechanism of action.
| ||
![]() | © 2005 Novartis Animal Health US, Inc. | |
![]() |
reconcile.com |
![]() | What is separation anxiety?Separation anxiety is a disease in which affected dogs may exhibit certain problematic behaviors when left alone, generally when you leave or immediately after. Separation anxiety is a clinical condition in your dog's brain. Your pet is not a bad dog. Your pet's behavior is the result of separation anxiety. |
Canine separation anxiety overview
But those behaviors may not happen because your dog is bad, poorly trained or spoiled. They may be the symptoms of a treatable condition: separation anxiety. Separation anxiety results when your pet becomes so upset by your absence the stress causes him to behave badly. While separation anxiety affects 10.7 million or 17 percent of dogs in the United States, it is a common but treatable condition. Veterinarians estimate nearly 60 percent of cases go undiagnosed. The most important thing for you to remember is that separation anxiety is a treatable health condition with a treatable solution.
Reconcile chewable tablets are available in 8, 16, 32, and 64 mg tablet strengths for oral administration to dogs. The active ingredient in RECONCILE chewable tablets is fluoxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI). | |
![]() Adverse reactions observed in dogs treated with Reconcile chewable tablets at a rate of 1% or greater were: seizures, weight loss, lethargy, depression, decreased appetite, vomiting, tremor, diarrhea, restlessness, otitis externa, disorientation, incoordination, constipation, excessive salivation. The effectiveness and clinical safety of Reconcile chewable tablets for long-term use (i.e. for more than 8 weeks) has not been evaluated. | |
| Working together, we can help pets live longer, healthier, higher-quality lives. | |
![]() | © Copyright 2007 Eli Lilly and Company. |
![]() |
pfizerah.com/slentrol |
The FDA has approved Slentrol for the safe and effective management of canine obesity, | |
Recognition of obesity in the family dog is sometimes difficult, and often owners may think their companion is large boned, has a thick coat or looks best when plump.   In addition, weight loss can be difficult for many owners to achieve in their dogs.   Diet and exercise -- the traditional approaches to weight loss -- can be effective if followed.   However, many dog owners experience frustration with these measures because of lack of time to exercise their dogs, and difficulty restricting food and treats.
Clinical PharmacologySlentrol is a selective microsomal triglyceride transfer protein inhibitor that blocks the assembly and release of lipoproteins into the bloodstream.   The mechanism of action for producing weight loss is not completely understood, but it seems to result from reduced fat absorption and a satiety signal from lipid-filled enterocytes.   Slentrol mainly acts locally in the gut to reduce appetite, increase fecal fat and produce weight loss in the management of obesity in dogs. | |
|
Adverse reactions associated with treatment with Slentrol:
|
![]() | Copyright © 2007 Pfizer Inc.   All rights reserved. |
Read the entire Science Made Simple series:  
|
|
Fair Use Notice |